News | Stents Peripheral | October 01, 2015

Zilver PTX Two-Year Results Support Drug-Eluting Stents in Superficial Femoral Artery

Data shows 85 percent freedom from total lesion revascularization in two years

Cook Medical, Zilver PTX, Japan PMS study, CIRSE 2015, two-year results

Image courtesy of Cook Medical

October 1, 2015 — Kimihiko Kichikawa, M.D., department of radiology at Nara Medical University in Japan, reported two-year results of the Zilver PTX post-market surveillance (PMS) study at the 2015 Cardiovascular and Interventional Radiology Society of Europe (CIRSE) meeting in Lisbon, Portugal. Kichikawa’s presentation focused on initial target data on lesion revascularization (TLR).

The two-year results indicate a continued low rate of revascularization in patients with complex lesions and comorbidities. No exclusion criteria were in the Japan PMS. The 1,075 lesions were complex, with an average lesion length of 14.7 cm, 42 percent total occlusions and 19 percent in-stent restenosis (ISR). In addition, 21 percent of Japanese patients in the PMS had critical limb ischemia (CLI), 59 percent had diabetes and 44 percent had renal disease.

The two-year freedom from TLR is 85 percent.

According to Kichikawa, the positive two-year Japan PMS results are consistent with other Zilver PTX trials and confirm the long-term benefits of the technology.

Two other major trials showed similar numbers at the two-year mark. Freedom from TLR was 85.7 percent in the randomized controlled trial (RCT) and was 83.3 percent in the single-arm study (SAS). The three trials enrolled more than 2,000 patients.

Zilver PTX has been approved for use in the European Union since August 2009 and in the United States and Japan since 2012. It is now approved in 48 countries.

Kichikawa is a paid consultant of Cook Medical.

For more information:

Related Content

News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Overlay Init